Tap to Ride! Monterey-Salinas Transit Becomes 1st in California to Offer Riders the Ability to Tap to Pay with Visa
11.5.2021 14:00:00 EEST | Business Wire | Press release
Today, in collaboration with Visa, Caltrans, Cybersource, Littlepay, and SC Soft, Monterey-Salinas Transit (MST) became the first transit agency in California to offer bus riders a contactless payment option. As cities begin to reopen, public transportation will play a critical role in recovery, and contactless payments can help provide a safe and easy experience for riders and transit operators seeking limited physical touchpoints and interactions. MST riders can now simply tap their contactless credit, debit, prepaid card or payment-enabled device on readers in MST buses for an easy and secure way to travel, without needing to purchase or load a separate transit card or handle cash while boarding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005504/en/
(Graphic: Business Wire)
Visa research shows that enabling tap to pay on transit systems like these can be good for economic recovery, bringing more than a 15% lift in transactions from merchants in surrounding neighborhoods1. MST is the fifth transit agency in the U.S. to accept tap to pay for fares, following Chicago, Miami, New York and Portland, OR. MST is also the first public transit system in the country that is located outside of a large urban area to introduce tap to pay fares – demonstrating contactless payments as a good fit for any size agency looking to enhance the customer experience.
“Visa recognizes the importance of expanding eligibility and access to fare payment options that meet the needs of a diverse set of transit riders,” said Brian Cole, SVP and head of North America product, Visa. “This effort with MST and Caltrans illustrates how open, contactless payments can support innovative and equitable fare policies to benefit riders and transit operators across the state.”
MST riders who tap will benefit from “fare capping” ensuring riders won’t pay more than $10.00 per day—as long as they pay with the same card or mobile wallet throughout the day. The tap to pay option on MST’s entire bus fleet is the first contactless payment demonstration of the California Integrated Travel Project (Cal-ITP), a Caltrans-led initiative to make travel simpler and more cost-effective for the 40 million California residents, served by 300-plus transit agencies, who collectively take approximately 1.3 billion2 passenger trips annually.
“We are committed to serving all of our riders and delivering new methods of ease and convenience,” said Carl Sedoryk, general manager and CEO, Monterey-Salinas Transit. “The availability of a contactless fare payment system means increased flexibility, and we are thrilled to be collaborating with Visa and Caltrans to bring the enhanced convenience and safety benefits of tap to pay to our community.”
Bringing the MST Demonstration to Life
Cybersource, a Visa solution, Littlepay, a transit-focused payments platform, and SC Soft, a transit ticketing and Automated Fare Collection specialist, have been critical in bringing the MST demonstration to life. Cybersource’s platform is powering the fast-to-market deployment of contactless solutions in the mass transit space, providing a full suite of payment and fraud management tools and an extensive network of partners and acquirers. Cybersource offers brand agnostic transit compliant processing solutions and enables easier implementation of digital payments for operators, while helping protect against fraud. Littlepay provides mass transit transaction processing, including the ability to cap fares and guarantee the best-value fare for frequent riders. SC Soft is a system integrator specializing in ticketing & Automated Fare Collection solutions for transit agencies around the world.
“Cybersource looks forward to supporting Cal-ITP partners to improve transit access within communities throughout the state,” said Fernando Souza, Vice President, Cybersource. “There is a great sense of urgency among transit operators to adopt these solutions and we are committed to powering secure, seamless contactless solutions in a world where no contact, touchless experiences are here to stay.”
“Removing barriers to transit ridership underscores what Cal-ITP is all about, and the launch of this contactless payment demonstration represents a significant step toward a simpler and more equitable public transit system throughout California,” said Caltrans Director Toks Omishakin.
Adoption of contactless payments continues to grow in the U.S. as more consumers realize they can pay for the things they need with a simple and secure tap. In the US, one in 10 face to face Visa transactions are now done with a tap, more than a 2x increase since the beginning of the pandemic, showcasing increased consumer preference for fast, touch-free payment experiences.
About Visa Inc.
Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable, and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, Visa’s Blog and @VisaNews.
__________
1
Visa Q2 FY21 Earnings Transcript
2
Caltrans, FY2018-2019
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005504/en/
Contact information
Visa
Tierney Deggelman
650 418 0352
tdeggelm@visa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
